Primary antibiotic resistance of Helicobacter pylori isolates is twofold more frequent in HIV-positive than HIV-negative individuals: A descriptive observational study - 2021
Primary antibiotic resistance of Helicobacter pylori isolates is twofold more frequent in HIV-positive than HIV-negative individuals: A descriptive observational study
[en] The antimicrobial susceptibility of Helicobacter pylori strains isolated from HIV-positive individuals is not well characterized. This study aimed to measure the prevalence and long-term trends associated with primary H. pylori antibiotic resistance, evaluate correlations with antibiotic consumption, and compare predictors for H. pylori antibiotic resistance between HIV-positive and HIV-negative individuals. In this longitudinal registry study, we evaluated consecutive adults with and without HIV infection, naïve to H. pylori treatment, who underwent upper gastrointestinal endoscopy and had a positive H. pylori culture, with susceptibility testing available, between 2004 and 2015. Outpatient antibiotic consumption data were based on nationwide aggregated numbers. H. pylori was isolated from gastric biopsies of 3008/8321 patients, 181/477 (37.9%) were HIV-positive and 2827/7844 (36.0%) HIV-negative. Overall cohort mean prevalence of H. pylori primary antibiotic resistance was 11.1% for clarithromycin, 17.8% levofloxacin, and 39.4% metronidazole. The prevalence of H. pylori primary resistance was significantly higher for these three drugs in HIV-positive individuals across the study period. Linear regression showed that the prevalence of clarithromycin and levofloxacin resistance correlated with the country aggregate daily dose consumption of macrolides and quinolones, respectively. Multivariable regression analysis showed that HIV infection is a strong independent risk factor for multiple H. pylori antibiotic resistance. In summary, HIV infection is a risk factor for carrying multi-resistant H. pylori strains and this is correlated with antibiotic consumption. Empirical therapies should be avoided in HIV-positive individuals. These data highlight the need to implement ongoing monitoring of H. pylori antimicrobial susceptibility among HIV-positive individuals. The study is registered at ISRCTN registry, number 13466428: https://www.isrctn.com/ISRCTN13466428.
Primary antibiotic resistance of Helicobacter pylori isolates is twofold more frequent in HIV-positive than HIV-negative individuals: A descriptive observational study
Publication date :
01 June 2021
Journal title :
MicrobiologyOpen
eISSN :
2045-8827
Volume :
10
Issue :
3
Pages :
e1184
Peer reviewed :
Peer Reviewed verified by ORBi
Research unit :
M136 - Chimie thérapeutique et Pharmacognosie
Research institute :
R550 - Institut des Sciences et Technologies de la Santé
Bell, B. G., Schellevis, F., Stobbering, E., Goossens, H., & Pringle, M. (2014). A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infectious Diseases, 14, 13.
Bogaerts, P., Berhin, C., Nizet, H., & Glupczynski, Y. (2006). Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter, 11(5), 441–445.
Butcher, L. D., Den Hartog, G., Ernest, P. B., & Crowe, S. E. (2017). Oxidative stress resulting from Helicobacter pylori infection contributes to gastric carcinogenesis. Cellular and Molecular Gastroenterology and Hepatology, 3(3), 316–322.
Chey, W. D., Leontiadis, G. I., Howden, C. W., & Moss, S. F. (2017). ACG clinical guideline: Treatment of Helicobacter pylori infection. American Journal of Gastroenterology, 112(2), 212–239.
Clinical and Laboratory Standards Institute (2009). Performance standards for antimicrobial susceptibility testing: 19th informational supplement (Vol. 29, no. 3, M100-S19). Wayne, PA. Clinical and Laboratory Standards Institute.
Coenen, S., Gielen, B., Blommaert, A., Beutels, P., Hens, N., & Goossens, H. (2014). Appropriate international measures for outpatient antibiotic prescribing and consumption: Recommendations from a national data comparison of different measures. Journal of Antimicrobial Chemotherapy, 69(2), 529–534.
Connolly, L. E., Edelstein, P. H., & Ramakrishnan, L. (2007). Why is long-term required to treat tuberculosis? PLoS Med, 4(3), e120.
Conway, B., & Tossonian, H. (2014). HIV/AIDS-A model of chronic oxidative stress and immune activation. In I. Laher (Ed.), Systems biology of free radical and antioxidants (pp. 3217–3238). Springer. https://doi.org/10.1007/978-3-642-30018-9_149
Crowe, S. E. (2019). Helicobacter pylori infection. New England Journal of Medicine, 380(12), 1158–1165.
Davidson, R. J., Davis, I., Willey, B. M., Rizg, K., Bolotin, S., Porter, V., Polsky, J., Daneman, N., McGeer, A., Yang, P., Scolnik, D., Rowsell, R., Imas, O., & Silverman, M. S. (2008). Antimalarial therapy selection for quinolone resistance among Escherichia coli in the absence of quinolone exposure, in Tropical South America. PLoS One, 3(7), e2727.
Eidt, S., Schrappe, M., & Fischer, R. (1995). Analysis of antral biopsy specimens for evidence of acquired mucosa-associated lymphoid tissue in HIV1-seropositive and HIV1-negative patients. Scandinavian Journal of Gastroenterology, 30(7), 635–639.
Ferreira, R. M., Pereira-Marques, J., Pinto-Ribeiro, I., Costa, J. L., Carneiro, F., Machado, J. C., & Figueiredo, C. (2018). Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut, 67(2), 226–236.
Filipec Kanizaj, T., Katicic, M., Skurla, B., Ticak, M., Plecko, V., & Kalenic, S. (2009). Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens. Helicobacter., 14(1), 29–35.
Gill, C. J., Mwanakasale, V., Fox, M. P., Chilengi, R., Tembo, M., Nsofwa, M., Chalwe, V., Mwananyanda, L., Mukwamataba, D., Malilwe, B., Champo, D., Macleod, W. B., Thea, D. M., & Hamer, D. H. (2008). Effect of presumptive cotrimoxazole prophylaxis on pneumococcal colonization rates, seroepidemiology and antibiotic resistance in Zambian infants: A longitudinal cohort study. Bulletin of the World Health Organization, 86(12), 929–938.
Gisbert, J. P., & Pajares, J. M. (2002). Review article: Helicobacter pylori “rescue” regimen when proton pump inhibitor-based triple therapies fail. Alimentary Pharmacology & Therapeutics, 16(6), 1047–1057.
Glupczynski, Y., Mégraud, F., Lopez-Brea, M., & Andersen, L. P. (2001). European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. European Journal of Clinical Microbiology and Infectious Diseases, 20(11), 820–823.
Graham, D. Y., & Shiotani, A. (2008). New concepts of resistance in the treatment of Helicobacter pylori infections. Nature Clinical Practice. Gastroenterology & Hepatology, 5(6), 321–331.
Iannone, A., Giorgio, F., Russo, F., Riezzo, G., Girardi, B., Pricci, M., Palmer, S. C., Barone, M., Principi, M., Strippoli, G. F., Di Leo, A., & Ierardi, E. (2018). New fecal test for non-invasive Helicobacter pylori detection. World Journal of Gastroenterology, 24(27), 3021–3029.
Kouitcheu Mabeku, L. B., Eyoum Bille, B., Tepap Zemnou, C., Tali Nguefack, L. D., & Leundji, H. (2019). Broad spectrum resistance in Helicobacter pylori isolated from gastric biopsies of patients with dyspepsia in Cameroon and efflux-mediated multiresistance detection in MDR isolates. BMC Infectious Diseases, 19(1), 880.
Krucke, G. W., Grimes, D. E., Grimes, R. M., & Dang, T. D. (2009). Antibiotic resistance in the Staphylococcus aureus containing cutaneous abscesses of HIV patients. American Journal of Emergency Medicine, 27(3), 344–347.
Lin, E. A., Zhang, X. S., Levine, S. M., Gill, S. R., Falush, D., & Blaser, M. J. (2009). Natural transformation of Helicobacter pylori involves the integration of short fragments DNA interrupted by Gaps of variable size. PLoS Path, 5(3), e1000337.
Malfertheiner, P., Megraud, F., O'Morain, C. A., Atherton, J., Axon, A. T., Bazzoli, F., Gensini, G. F., Gisbert, J. P., Graham, D. Y., Rokkas, T., & El-Omar, E. M. (2012). Management of Helicobacter pylori infection—the Maastricht IV/Florence consensus report. Gut, 61(5), 646–664.
Malfertheiner, P., Megraud, F., O'Morain, C. A., Gisbert, J. P., Kuipers, E. J., Axon, A. T., Bazzoli, F., Gasbarrini, A., Atherton, J., Graham, D. Y., Hunt, R., Moayyedi, P., Rokkas, T., Rugge, M., Selgrad, M., Suerbaum, S., Sugano, K., El-Omar, E. M.; European Helicobacter and Microbiota Study Group and Consensus Panel (2017). Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut, 66(1), 6–30.
Malfertheiner, P., Mégraud, F., O'Morain, C., Hungin, A. P. S., Jones, R., Axon, A., Graham, D. Y., Tytgat, G., European Helicobacter Pylori Study Group (EHPSG) (2002). Current concepts in the management of Helicobacter pylori infection–the Maastricht 2–2000 Consensus Report. Alimentary Pharmacology & Therapeutics, 16(2), 167–180.
Megraud, F., Coenen, S., Versporten, A., Kist, M., Lopez-Brea, M., Hirschl, A. M., Andersen, L. P., Goossens, H., & Glupczynski, Y.; Study Group Participants (2013). Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut, 62(1), 34–42.
Miendje Deyi, V. Y., Bontems, P., Vanderpas, J., De Koster, E., Ntounda, R., Van den Borre, C., Cadranel, S., & Burette, A. (2011). Routine survey determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years (1999 to 2009) in Belgium. Journal of Clinical Microbiology, 49(6), 2200–2209.
Mouery, K., Rader, B. A., Gaynor, E. C., & Guillemin, K. (2006). The stringent response is required for Helicobacter pylori survival of stationary phase, exposure to acid, and aerobic shock. Journal of Bacteriology, 188(15), 5494–5500.
Nevin, T. D., Morgan, C. J., Graham, D. Y., & Genta, R. M. (2014). Helicobacter pylori gastritis in HIV-infected patients: A review. Helicobacter, 19(5), 323–329.
Ngalani, O. J. T., Mbaveng, A. T., Marbou, W. J. T., Ngai, R. Y., & Kuete, V. (2019). Antibiotic resistance of enteric bacteria in HIV-Infected patients at the Banka Ad-Lucem Hospital, West region of Cameroon. Canadian Journal of Infectious Diseases and Medical Microbiology, 2019, 9381836.
Nkuize, M., De Wit, S., Muls, V., Delforge, M., Miendje Deyi, V. Y., Cadière, G. B., & Buset, M. (2015). HIV-Helicobacter pylori co-infection: Antibiotic resistance, prevalence, and risk factors. PLoS One, 10(12), e0145119.
Nkuize, M., Vanderpas, J., Buset, M., Delforge, M., Cadière, G.-B., De Wit, S. Failure to eradicate Helicobacter pylori infection is more frequent among HIV-positive patients. HIV Medicine. https://doi.org/10.1111/hiv.13083. [Epub ahead of print]
O'Rourke, E. J., Chevalier, C., Pinto, A. V., Thiberge, J. M., Ielpi, L., Labigne, A., & Radicella, J. P. (2003). Pathogen DNA as target for host-generated oxidative stress: Role for repair of bacterial DNA damage in Helicobacter pylori colonization. Proceedings of the National Academy of Sciences of the United States of America, 100(5), 2789–2794.
Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents (2020). Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. (Accessed February 11, 2020)
Pantaleo, G., Fauci, A. S. (1996). Immunopathogenesis of HIV infection. Annu Rev Microbiol, 50, 825-854.
Pero, R., Brancaccio, M., Laneri, S., Biasi, M. G., Lombardo, B., & Scudiero, O. (2019). A novel view of human Helicobacter pylori Infections: Interplay between microbiota and beta-defensins. Biomolecules, 9(6), 237.
Raymond, J., Lamarque, D., Kalach, N., Chaussade, S., & Burucoa, C. (2010). High level of antimicrobial resistance of French Helicobacter pylori isolates. Helicobacter, 15(1), 21–27.
Roe, I. H., Son, S. H., Oh, H. T., Choi, J., Shin, J. H., Lee, J. H., & Hah, Y. C. (1999). Changes in the evolution of the antigenic profiles and morphology during coccoid conversion of Helicobacter pylori. Korean Journal of Internal Medicine, 14(1), 9–14.
Saag, M. S., Benson, C. A., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Mugavero, M. J., Sax, P. E., Smith, D. M., Thompson, M. A., Buchbinder, S. P., del Rio, C., Eron, J. J., Fätkenheuer, G., Günthard, H. F., Molina, J.-M., Jacobsen, D. M., & Volberding, P. A. (2018). Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel. JAMA, 320(4), 379–396.
Sarfo, F. S., Eberhardt, K. A., Dompreh, A., Kuffour, E. O., Soltau, M., Schachscheider, M., Drexler, J. F., Eis-Hübinger, A. M., Häussinger, D., Oteng-Seifah, E. E., Bedu-Addo, G., Phillips, R. O., Norman, B., Burchard, G., & Feldt, T. (2015). Helicobacter pylori infection is associated with higher CD4 T cell counts and lower HIV-1 viral loads in ART-Naïve HIV-positive patients in Ghana. PLoS One, 10(11), e0143388.
Saxena, D., Li, Y., Yang, L., Pei, Z., Poles, M., Abrams, W. R., & Malamud, D. (2012). Human microbiome and HIV/AIDS. Current HIV/AIDS Reports, 9(1), 44–51.
Sugano, K., Tack, J., Kuipers, E. J., Graham, D. Y., El-Omar, E. M., Miura, S., Haruma, K., Asaka, M., Uemura, N., Malfertheiner, P.; faculty members of Kyoto Global Consensus Conference (2015). Kyoto global consensus report on Helicobacter pylori gastritis. Gut, 64(9), 1–15.
Thung, I., Aramin, H., Vavinskaya, V., Gupta, S., Park, J. Y., Crowe, S. E., & Valasek, M. A. (2016). Review article: The global emergence of Helicobacter pylori antibiotic resistance. Alimentary Pharmacology & Therapeutics, 43(4), 514–533.
Vakil, N., & Megraud, F. (2007). Eradication therapy for Helicobacter pylori. Gastroenterology, 133(3), 985–1001.
Wells, D. H., & Gaynor, E. (2006). Helicobacter pylori initiates the stringent response upon nutriment and pH downshift. Journal of Bacteriology, 188(10), 3726–3729.
Wong, W. M., Gu, Q., Wang, W. H., Fung, F.- M.-Y., Berg, D. E., Lai, K. C., Xia, H.- H.-X., Hu, W. H. C., Chan, C. K., Chan, A.- O.-O., Yuen, M.-F., Hui, C.-K., Lam, S. K., & Wong, B.- C.-Y. (2003). Effects of primary metronidazole and clarithromycin resistance to Helicobacter pylori on omeprazole, metronidazole, and clarithromycin triple-therapy regimen in a region with high rates of metronidazole resistance. Clinical Infectious Diseases, 37(7), 882–889.
